Compare ADMA Biologics Inc (ADMA) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Omnicom Group Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Omnicom Group Inc. trades at $85.74 (market cap $23.22B). The key difference: Omnicom Group Inc. is far larger — about 10.7× ADMA Biologics Inc's market cap, and Omnicom Group Inc. pays a 3.78% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | OMC | |
|---|---|---|
Market Cap | $2.18B | $23.22B |
Sector | Health | Media |
52-Week High | $20.38 | $86.22 |
52-Week Low | $7.60 | $67.27 |
Enterprise Value | $2.25B | $31.30B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Omnicom Group (OMC) trades at $85.24, up 3.31% today, with a bullish technical outlook supported by moving averages and key resistance at $86. Recent Q2 2026 earnings beat estimates with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company maintains a $0.80 quarterly dividend and benefits from post-merger synergies with Interpublic Group.
OMC presents a value opportunity with a low P/S of 0.96 and consensus price target of $107, but high P/E of 230.38 and integration risks post-acquisition warrant caution. Analyst sentiment is mixed with 32% buy ratings, highlighting growth potential against margin pressures and competitive threats in the advertising sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
